author-photo

Gary Vanasse

Novartis

13

Papers

625

Citations

Citation Trend

Filter By

Papers (5) Sort By

Journal Conference Others

COMBINATION THERAPY USING ASCIMINIB PLUS IMATINIB (IMA) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA (CML): RESULTS FROM A PHASE 1 STUDY: S883

2019
Show All
- Source
- Cite
- Save
Citations (5)
Combination of Asciminib+Nilotinib or Asciminib+Dasatinib in Previously Treated Chronic Myeloid Leukemia (CML) Patients: Phase 1 Study Results

2019 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (2)
Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy

2016 Blood
Show All
- Source
- Cite
- Save
Citations (19)
Abstract 2522: Molecular and cellular mechanisms underlying the therapeutic efficacy of the combination of JAK inhibitor, ruxolitinib, PIM inhibitor, LGH447, and CDK4/6 inhibitor, LEE011, in a preclinical model of myeloproliferative neoplasia

2015 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia

2015 Science Advances
Show All
- Source
- Cite
- Save
Citations (56)